From USFDA
Strides Arcolab announced that it has received approval from the United States Food & Drug Administration (USFDA) for Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg.The product will be manufactured at the Company's Oral Dosage facility in Bangalore and marketed by Strides in the US market. The product will be launched in the markets immediately.
According to IMS data, the US market for Lamivudine and Zidovudine Tablets is approximately USD 120 million.
Powered by Capital Market - Live News
